Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial

Detalhes bibliográficos
Autor(a) principal: Estevão,Rodrigo Augusto Fernandes
Data de Publicação: 2007
Outros Autores: Baracat,Edmund Chada, Logullo,Ângela Flávia, Oshima,Celina Tizuko Fujiyama, Nazário,Afonso Celso Pinto
Tipo de documento: Artigo
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802007000600008
Resumo: CONTEXT AND OBJECTIVE: Mammary fibroadenoma is a disease that affects a large number of women of reproductive age. The aim of this study was to evaluate the proliferative activity of mammary fibroadenoma through expression of Ki-67 and c-myc antigens, following administration of oral contraceptive with or without estriol. DESIGN AND SETTING: Placebo-controlled double-blind randomized clinical trial in the Mastology Sector of the Department of Gynecology, Universidade Federal de São Paulo. METHODS: Thirty-three fibroadenoma patients were studied. Ten women (group 1) took an oral contraceptive constituted by levonorgestrel and ethinyl estradiol together with placebo manufactured in the same capsule for four consecutive cycles with a seven-day interval between them. The other 23 patients (group 2) took the same oral contraceptive together with estriol, which was put into the same capsule and used in the same way as among the group 1 patients. After four cycles, the nodules were surgically removed and sent for immunohistochemical analysis of Ki-67 and c-myc expression. RESULTS: The Ki-67 and c-myc analysis did not reveal any significant differences between the study groups. The values were 9.16 and 10.54 for group 1 and 10.86 and 17.03 for group 2, respectively. There was a tendency towards higher expression of antigens in group 2. CONCLUSION: Our results showed that there was no significant statistical difference in Ki-67 and c-myc expression between our study groups, but only a tendency towards higher expression among users of oral contraceptives containing estriol.
id APM-1_09fa6095a26aaf46336c6cc1fe831c97
oai_identifier_str oai:scielo:S1516-31802007000600008
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trialFibroadenomaContraceptives oralEstriolKi-67 antigenMyc genesCONTEXT AND OBJECTIVE: Mammary fibroadenoma is a disease that affects a large number of women of reproductive age. The aim of this study was to evaluate the proliferative activity of mammary fibroadenoma through expression of Ki-67 and c-myc antigens, following administration of oral contraceptive with or without estriol. DESIGN AND SETTING: Placebo-controlled double-blind randomized clinical trial in the Mastology Sector of the Department of Gynecology, Universidade Federal de São Paulo. METHODS: Thirty-three fibroadenoma patients were studied. Ten women (group 1) took an oral contraceptive constituted by levonorgestrel and ethinyl estradiol together with placebo manufactured in the same capsule for four consecutive cycles with a seven-day interval between them. The other 23 patients (group 2) took the same oral contraceptive together with estriol, which was put into the same capsule and used in the same way as among the group 1 patients. After four cycles, the nodules were surgically removed and sent for immunohistochemical analysis of Ki-67 and c-myc expression. RESULTS: The Ki-67 and c-myc analysis did not reveal any significant differences between the study groups. The values were 9.16 and 10.54 for group 1 and 10.86 and 17.03 for group 2, respectively. There was a tendency towards higher expression of antigens in group 2. CONCLUSION: Our results showed that there was no significant statistical difference in Ki-67 and c-myc expression between our study groups, but only a tendency towards higher expression among users of oral contraceptives containing estriol.Associação Paulista de Medicina - APM2007-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802007000600008Sao Paulo Medical Journal v.125 n.6 2007reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/S1516-31802007000600008info:eu-repo/semantics/openAccessEstevão,Rodrigo Augusto FernandesBaracat,Edmund ChadaLogullo,Ângela FláviaOshima,Celina Tizuko FujiyamaNazário,Afonso Celso Pintoeng2008-02-26T00:00:00Zoai:scielo:S1516-31802007000600008Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2008-02-26T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial
title Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial
spellingShingle Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial
Estevão,Rodrigo Augusto Fernandes
Fibroadenoma
Contraceptives oral
Estriol
Ki-67 antigen
Myc genes
title_short Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial
title_full Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial
title_fullStr Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial
title_full_unstemmed Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial
title_sort Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: randomized clinical trial
author Estevão,Rodrigo Augusto Fernandes
author_facet Estevão,Rodrigo Augusto Fernandes
Baracat,Edmund Chada
Logullo,Ângela Flávia
Oshima,Celina Tizuko Fujiyama
Nazário,Afonso Celso Pinto
author_role author
author2 Baracat,Edmund Chada
Logullo,Ângela Flávia
Oshima,Celina Tizuko Fujiyama
Nazário,Afonso Celso Pinto
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Estevão,Rodrigo Augusto Fernandes
Baracat,Edmund Chada
Logullo,Ângela Flávia
Oshima,Celina Tizuko Fujiyama
Nazário,Afonso Celso Pinto
dc.subject.por.fl_str_mv Fibroadenoma
Contraceptives oral
Estriol
Ki-67 antigen
Myc genes
topic Fibroadenoma
Contraceptives oral
Estriol
Ki-67 antigen
Myc genes
description CONTEXT AND OBJECTIVE: Mammary fibroadenoma is a disease that affects a large number of women of reproductive age. The aim of this study was to evaluate the proliferative activity of mammary fibroadenoma through expression of Ki-67 and c-myc antigens, following administration of oral contraceptive with or without estriol. DESIGN AND SETTING: Placebo-controlled double-blind randomized clinical trial in the Mastology Sector of the Department of Gynecology, Universidade Federal de São Paulo. METHODS: Thirty-three fibroadenoma patients were studied. Ten women (group 1) took an oral contraceptive constituted by levonorgestrel and ethinyl estradiol together with placebo manufactured in the same capsule for four consecutive cycles with a seven-day interval between them. The other 23 patients (group 2) took the same oral contraceptive together with estriol, which was put into the same capsule and used in the same way as among the group 1 patients. After four cycles, the nodules were surgically removed and sent for immunohistochemical analysis of Ki-67 and c-myc expression. RESULTS: The Ki-67 and c-myc analysis did not reveal any significant differences between the study groups. The values were 9.16 and 10.54 for group 1 and 10.86 and 17.03 for group 2, respectively. There was a tendency towards higher expression of antigens in group 2. CONCLUSION: Our results showed that there was no significant statistical difference in Ki-67 and c-myc expression between our study groups, but only a tendency towards higher expression among users of oral contraceptives containing estriol.
publishDate 2007
dc.date.none.fl_str_mv 2007-11-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802007000600008
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802007000600008
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-31802007000600008
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv Sao Paulo Medical Journal v.125 n.6 2007
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1754209262083506176